AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11250991
Drug: Three cycles
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three cycles of BEP chemotherapy
Trial: 11250991
Drug: Three-day schedule
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-day schedule of BEP chemotherapy
Trial: 30091545
Drug: Surface electromyogram
RxNorm normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surface electromyogram biofeedback therapy (sEMGBF)
Trial: 30091545
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (ACE+sEMGBF)
Trial: 28832550
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin (BoNT) treatment
Trial: 28832550
Drug: BoNT treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BoNT treatment (after 4-7 weeks and again after 11-15 weeks)
Trial: 3510268
Drug: Decongestant-antihistamine mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decongestant-antihistamine mixture (Dimetapp)
Trial: 29351861
Drug: GOALS therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GOALS therapy
Trial: 29351861
Drug: GOALS therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GOALS therapy and Treatment as usual
Trial: 23110471
Drug: Olmesartan 40
RxNorm normalized name: HCTZ 25/OLMESARTAN 40MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan 40 mg, Amlodipine 10 mg, Hydrochlorothiazide 25 mg
Trial: 23110471
Drug: Olmesartan 40
RxNorm normalized name: HCTZ 25/OLMESARTAN 40MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan 40 mg, Amlodipine 10 mg
Trial: 23110471
Drug: Olmesartan 40
RxNorm normalized name: HCTZ 25/OLMESARTAN 40MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan 40 mg, Hydrochlorothiazide 25 mg
Trial: 23110471
Drug: Amlodipine 10
RxNorm normalized name: amlodipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine 10 mg, Hydrochlorothiazide 25 mg
Trial: 27093744
Drug: Captopril 12.50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 12.50 mg
Trial: 27093744
Drug: Captopril 25.00
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 25.00 mg
Trial: 2317417
Drug: Midazolam (0.01-0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.01-0.2 mg kg-1 h-1)
Trial: 28215471
Drug: RP5063 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RP5063 (all doses combined)
Trial: 21883353
Drug: Tobramycin once
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tobramycin once daily
Trial: 21883353
Drug: Tobramycin three
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tobramycin three times daily
Trial: 17309949
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy (291 patients in parallel group trials)
Trial: 17309949
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy (in crossover trials, 265 patients)
Trial: 15152059
Drug: Cardiac-resynchronization therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac-resynchronization therapy with a pacemaker
Trial: 15152059
Drug: Cardiac-resynchronization therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac-resynchronization therapy with a pacemaker-defibrillator
Trial: 15152059
Drug: Optimal pharmacologic
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal pharmacologic therapy alone
Trial: 11382723
Drug: Nematode anticoagulant
RxNorm normalized name: Recombinant nematode anticoagulant protein-2
DrugBank: Anpocogin (DB06552)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nematode anticoagulant protein c2 3.5 microgram/kg
Trial: 8489989
Drug: Fentanyl subcutaneous
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl subcutaneous infusion (F-SC)
Trial: 8489989
Drug: Fentanyl plus
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl plus bupivacaine infusion (F-PLX)
Trial: 3114663
Drug: 240 mg
RxNorm normalized name: aspirin 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 mg of crystalline melatonin (aMT) administered orally
Trial: 2802036
Drug: Antibiotic mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic mouthwash
Trial: 21810106
Drug: 16 sessions
RxNorm normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 sessions of psychotherapy combined with pharmacotherapy
Trial: 21810106
Drug: 8 sessions
RxNorm normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 sessions of psychotherapy combined with pharmacotherapy
Trial: 21810106
Drug: Both 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both 8 and 16 sessions of psychotherapy combined with pharmacotherapy
Trial: 19537522
Drug: Escitalopram 10
RxNorm normalized name: escitalopram 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram 10 mg tablet (test preparation)
Trial: 19537522
Drug: Escitalopram 10
RxNorm normalized name: escitalopram 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram 10 mg tablet (reference preparation)
Trial: 16702182
Drug: Rituximab maintenance
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab maintenance treatment (375 mg/m2, one injection every 2 months for six times)
Trial: 16702182
Drug: Observation (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observation (control group for maintenance treatment)
Trial: 8342318
Drug: 1991‐1992 trivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1991‐1992 trivalent split influenza vaccine (A/Singapore/6/86 (H1N1), A/Beijing/353/89 (H3N2), B/Yamagata/16/88)
Trial: 3569766
Drug: Cisapride (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride (10 mg, q.i.d. for 4 weeks)
Trial: 27986357
Drug: Less dilated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Less dilated left ventricles (EDVI < 90 mL/m2)
Trial: 27986357
Drug: Severely dilated
RxNorm normalized name: phenylephrine hydrochloride Ophthalmic Solution [AK-Dilate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Severely dilated left ventricles (EDVI ≥ 90 mL/m2)
Trial: 25102205
Drug: Norepinephrine/low volume
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine/low volume group (2 μg/kg per hour norepinephrine + 1 ml/kg per hour initially and 3 ml/kg per hour crystalloid infusion after cystectomy)
Trial: 25102205
Drug: Standard crystalloid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard crystalloid infusion group (6 ml/kg per hour throughout surgery)
Trial: 25102205
Drug: Standard crystalloid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard crystalloid infusion group
Trial: 18971883
Drug: Piracetam (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piracetam (12 g at the beginning of the operation)
Trial: 12707726
Drug: FLAG-IDA (fludarabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FLAG-IDA (fludarabine 30 mg/m(2), AraC 2 g/m(2) for 5 days, idarubicin 10 mg/m(2) for 3 days, G‐CSF 5 micro g/kg from day +6 until neutrophil recovery)
Trial: 7494233
Drug: Intra-arterial chemotherapy
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial chemotherapy via two-vessel treatment
Trial: 7494233
Drug: Intra-arterial chemotherapy
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial chemotherapy via one-vessel treatment
Trial: 7494233
Drug: Intra-arterial chemotherapy
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial chemotherapy via middle-cerebral artery treatment
Trial: 7494233
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group in the BTCG phase III trial of intra-arterial chemotherapy
Trial: 1788749
Drug: i.v. infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. infusion of 40 micrograms PGE1 in 125 ml saline over 60 min
Trial: 1788749
Drug: i.a. infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.a. infusion of 10 micrograms PGE1 in 25 ml saline over 30 min
Trial: 6756705
Drug: Angiotensin II
RxNorm normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Angiotensin II infusion (5, 10, and 20 ng/kg/min)
Trial: 6756705
Drug: Control infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control infusions (placebo)
Trial: 29482649
Drug: Paclitaxel plus
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel plus 5-fluorouracil (TF) concurrent with radiotherapy (5-fluorouracil 300 mg/m2 continuous infusion for 96 h plus paclitaxel 50 mg/m2 on day 1 for 5 weeks) followed by consolidation chemotherapy (5-fluorouracil 1800 mg/m2 continuous infusion for 72 h plus paclitaxel 175 mg/m2 on day 1 for 2 cycles)
Trial: 29482649
Drug: Cisplatin plus
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin plus 5-fluorouracil (PF) concurrent with radiotherapy (cisplatin 25 mg/m2/d on days 1-3 plus 5-fluorouracil 1800 mg/m2 continuous infusion for 72 h for 2 cycles) followed by consolidation chemotherapy for 2 cycles
Trial: 22374842
Drug: Flour inhalation
RxNorm normalized name: Flours
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flour inhalation challenge
Trial: 22374842
Drug: Control inhalation
RxNorm normalized name: Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control inhalation challenge
Trial: 21186929
Drug: Buprenorphine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine treatment combined with contingency management for up to 12 weeks
Trial: 15703367
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg dexloxiglumide (3 times a day on days 17-20, followed by a single dose on day 21)
Trial: 11907926
Drug: Various treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various treatments for menopause (specific treatments not detailed)
Trial: 7665807
Drug: Fluoxetine continuation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine continuation therapy
Trial: 2468920
Drug: Verapamil (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (80 mg b.i.d.)
Trial: 2468920
Drug: Xamoterol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xamoterol (200 mg b.i.d.)
Trial: 792358
Drug: Amikacin (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amikacin (150 or 200 mg every hr)
Trial: 792358
Drug: Gentamicin (60-80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin (60-80 mg every 8 hr)
Trial: 24201232
Drug: Risperidone plus
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Risperidone plus amantadine (100 mg/d for patients <30 kg or 150 mg/d for patients >30 kg)
Trial: 19892078
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (Seeking Safety; SS) plus treatment-as-usual (TAU)
Trial: 19892078
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (Seeking Safety; SS)
Trial: 9236587
Drug: Amoxicillin-clavulanate for
RxNorm normalized name: amoxicillin / clavulanate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin-clavulanate for 14 days
Trial: 9236587
Drug: Amoxicillin-clavulanate for
RxNorm normalized name: amoxicillin / clavulanate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin-clavulanate for 28 days
Trial: 2677260
Drug: 5‐fluorouracil (5‐FU),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐fluorouracil (5‐FU), 600 mg/m2/week for 6 weeks (arm A)
Trial: 2677260
Drug: 5‐FU +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐FU + folinic acid (FA), 200 mg/m2/week for 6 weeks (arm B)
Trial: 2677260
Drug: 5‐FU, 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐FU, 600 mg/m2/week for 6 weeks (arm A)
Trial: 2677260
Drug: 5‐FU +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐FU + FA, 200 mg/m2/week for 6 weeks (arm B)
Trial: 31830535
Drug: Video game-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Video game-based occupational therapy (VG)
Trial: 27841946
Drug: Intensive glycemic
RxNorm normalized name: Glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive glycemic control (BG: 100‐140 mg/dL)
Trial: 27841946
Drug: Conservative glycemic
RxNorm normalized name: Glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative glycemic control (BG: 141‐180 mg/dL)
Trial: 24197754
Drug: Sham group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham group received the same treatment with 1 Hz (n=15).
Trial: 12638032
Drug: Phytosterol-enriched spread
RxNorm normalized name: phytosterols
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phytosterol-enriched spread (2 x 10 g daily)
Trial: 2102123
Drug: Controlled clinical
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled clinical trial (medical treatment)
Trial: 30641691
Drug: Glimepiride 2
RxNorm normalized name: glimepiride 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride 2 mg twice daily + l-carnitine 1 g twice daily
Trial: 30641691
Drug: Glimepiride 2
RxNorm normalized name: glimepiride 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride 2 mg twice daily
Trial: 21866652
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Chinese medicine and chemotherapy
Trial: 3311432
Drug: Midazolam (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (12.5 mg) with ketamine (250 mg)
Trial: 3311432
Drug: Diazepam (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (20 mg) with ketamine (250 mg)
Trial: 29914924
Drug: Oral cephalexin
RxNorm normalized name: Cephalexin
DrugBank: Cephalexin (DB00567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cephalexin 500 mg four times daily
Trial: 29914924
Drug: Intravenous cefazolin
RxNorm normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous cefazolin 2 g daily plus oral probenecid 1 g daily
Trial: 26954311
Drug: Apremilast (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apremilast (30 mg twice weekly)
Trial: 18414108
Drug: Travoprost ophthalmic
RxNorm normalized name: travoprost ophthalmic
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Travoprost ophthalmic solution 0.004% (BAK-free)
Trial: 18414108
Drug: Travoprost ophthalmic
RxNorm normalized name: travoprost ophthalmic
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Travoprost ophthalmic solution 0.004% (with BAK)
Trial: 16828939
Drug: Influenza vaccination
RxNorm normalized name: Haemophilus influenzae b (Ross strain) capsular polysaccharide meningococcal protein conjugate vaccine Injection [PedvaxHIB]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Influenza vaccination (2004/2005 influenza vaccine)
Trial: 8629722
Drug: Assured treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assured treatment design
Trial: 6397333
Drug: Flurbiprofen 200
RxNorm normalized name: flurbiprofen 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen 200 mg to 400 mg daily
Trial: 6397333
Drug: Piroxicam 20
RxNorm normalized name: piroxicam 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam 20 mg to 40 mg daily
Trial: 11593107
Drug: Irbesartan 150
RxNorm normalized name: irbesartan 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan 150 mg once daily
Trial: 11593107
Drug: Losartan 50
RxNorm normalized name: LOSARTAN 50MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 50 mg b.i.d.
Trial: 9704709
Drug: Filgrastim 5
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Filgrastim 5 microg/kg plus SCF (doses of 5, 10, 15, and 20 microg/kg)
Trial: 7989631
Drug: Hypnosis before
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypnosis before injection
Trial: 2722725
Drug: Cefmetazole (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefmetazole (2 g single dose administered IV within 90 min of operation)
Trial: 2722725
Drug: Cefoxitin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoxitin (2 g single dose preoperative and two additional doses at 6 h intervals post-surgery)
Trial: 26501700
Drug: GLN-supplemented parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLN-supplemented parenteral nutrition (GLN-PN)
Trial: 26501700
Drug: Standard GLN-free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard GLN-free parenteral nutrition (STD-PN)
Trial: 20862932
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment at Renying (ST 9), Fengfu (GV 16), Baihui (GV 20)
Trial: 20862932
Drug: Shenmai injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenmai injection combined with 250 mL 5% Glucose injection
Trial: 10370789
Drug: Platinum drug
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platinum drug treatment
Trial: 8683652
Drug: Post-treatment instructions
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment instructions
Trial: 31155298
Drug: Conventional root
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional root canal treatment (CRCT)
Trial: 26025328
Drug: 480 mg
RxNorm normalized name: magaldrate 480 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 480 mg choline/day
Trial: 26025328
Drug: 930 mg
RxNorm normalized name: PETROLATUM 930 mg in 1 g TOPICAL OINTMENT [Vitamins A and D]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 930 mg choline/day
Trial: 15743150
Drug: Hormonal therapy
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormonal therapy with external-beam radiation (EBRT)
Trial: 15743150
Drug: Hormonal therapy
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormonal therapy with brachytherapy
Trial: 15743150
Drug: Whole-pelvic EBRT
RxNorm normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-pelvic EBRT and hormonal therapy
Trial: 15743150
Drug: Hormonal therapy
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormonal therapy with brachytherapy without pelvic radiotherapy
Trial: 1995258
Drug: Nifedipine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (up to 20 mg)
Trial: 6401229
Drug: Intravenous nitroglycerin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous nitroglycerin (TNG)
Trial: 31889177
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A (rods and implants with DEAE-Dextran and Quil-A)
Trial: 31889177
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B (rods and implants with either DEAE-Dextran or Quil A)
Trial: 28190578
Drug: Quadpill (irbesartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadpill (irbesartan 37.5 mg, amlodipine 1.25 mg, hydrochlorothiazide 6.25 mg, atenolol 12.5 mg)
Trial: 25403919
Drug: AG-PUFA (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AG-PUFA (3 g/day for 8 weeks)
Trial: 25403919
Drug: EE-PUFA (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EE-PUFA (3 g/day for 8 weeks)
Trial: 24954344
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine combined with intravenous patient-controlled analgesia (ITM-IVPCA)
Trial: 22882288
Drug: Aggressive parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive parenteral nutrition (PN) (amino acids 3 g/kg per day and lipids 2 g/kg per day on first day of life)
Trial: 22882288
Drug: Conventional PN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional PN (amino acids 1.5 g/kg per day and lipids 1 g/kg per day on first day of life)
Trial: 19543114
Drug: Concentrated formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concentrated formula (CF) 87 kcal/100 mL for 8 weeks
Trial: 19543114
Drug: Standard formula
RxNorm normalized name: Standard formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard formula (SF) 67 kcal/100 mL for 8 weeks